Cannabis Science Full Report: What a Phase 2 CBD Autism Trial Found
A 2026 phase 2 open-label cannabidiol autism trial reported early symptom improvement signals with mostly mild adverse events. The study was small and uncontrolled, limiting efficacy conclusions. This trial offers preliminary clinical insights into…
CED Cannabis Science Digest: 3 Evidence and Measurement Signals Worth Watching
This digest highlights 3 evidence and measurement signals in cannabis science that help separate clinical proof from preliminary data. It covers systematic reviews, a human HIV biomarker study, and improved cannabinoid measurement methods. These signals…
Why Cannabis Loyalty Is Built on Trust, Not High THC Potency
Cannabis consumer trust is becoming the key factor in product loyalty rather than high THC potency. Patients increasingly prefer balanced formulations and lower-dose products. This shift highlights the importance of trust and consistent quality in…
CED Cannabis Science Digest: 3 Additional Clinical Signals Worth Watching
This digest highlights 3 additional cannabis science signals that sharpen clinical counseling and research endpoints. These signals include Parkinson's nonmotor symptoms, cannabis use disorder endpoints, and cannabinoid hyperemesis syndrome…
Cannabis Use in Early-Onset Psychosis: What the New Meta-Analysis Shows
A 2026 meta-analysis found cannabis use and cannabis use disorder are common in early-onset psychosis and linked to a more complicated clinical picture, but it does not prove causation.
Cannabis for Tourette Tics: What the Meta-Analysis Does and Does Not Prove
A 2026 systematic review and meta-analysis reported reductions in tic severity and premonitory urges with cannabis-based medicines in Tourette syndrome. The signal is promising, but the evidence base is still small, mixed, and not enough to settle…
Cannabinoids for Alzheimer’s Agitation: What a New Meta-Analysis Adds
A new systematic review and meta-analysis found lower agitation and neuropsychiatric symptom scores with cannabinoid-based therapies in Alzheimer’s disease, but the evidence remains limited by small trials, heterogeneous products, short follow-up, and…
CED Cannabis Science Digest: Immune Activation and CB1-Target Insights
This digest highlights immune activation cannabis research focusing on HIV-linked inflammatory signaling, CB1-target drug design hurdles, and preclinical CBD brain delivery. These three verified cannabis science signals clarify current evidence limits…
CED Cannabis Science Digest: 3 Sleep, Oncology, and Pain Cannabis Signals Worth Watching
This digest highlights 3 verified cannabis science signals focusing on sleep, oncology communication, and pain research. These signals provide valuable insights for clinicians and researchers. They emphasize the importance of product type, patient…
CED Cannabis Science Digest: 3 Clinical-Caution Cannabis Signals Worth Watching
This digest highlights 3 clinical-caution cannabis signals from recent studies, focusing on safety and efficacy limits. The signals include a negative CB1 trial, FAAH translational challenges, and weak PTSD evidence. These findings help clinicians set…
